Human Papilloma Virus (HPV)-related cervical cancer (CC) still drives cancer-related mortality in low-to-middle income countries (LMICs), exacerbated by disparities in HPV screening, HPV vaccination status, specialist availability, and treatment costs compared to higher-income countries. This study describes how botanical nutraceuticals may provide a viable, low-cost strategy to target molecular hallmarks of HPV-related CC that would specifically benefit regions with limited access to specialized oncologists or radiotherapy infrastructure. Additionally, this study discusses recent studies that indicate how these botanical agents may double as radio-sensitizing agents, which may decrease the frequency of radiation therapy. We also discuss how topical use could potentially overcome the primary issue of bioavailability, and modern innovations in utilizing chitosan-based hydrogels and mucoadhesive wafers that enhance localized concentrations of nutraceuticals. Botanical therapeutics represent a scalable, economically feasible adjuvant to standard care in CC in LMICs. By leveraging widely available natural products, we can work towards ensuring that no woman is left without a treatment option.

Cervical cancer, Nutraceuticals, Plant extracts, Health disparities, Low-to-middle income countries